This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Zymeworks (ZYME) Gets a Buy from Wells Fargo

Tipranks - Tipranks - Wed Jun 3, 5:00AM CDT

In a report released yesterday, Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on Zymeworks, with a price target of $34.00. The company’s shares closed yesterday at $24.54.

Claim 55% Off TipRanks

According to TipRanks, Fortea Verdejo is a 5-star analyst with an average return of 41.3% and a 75.38% success rate. Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Genmab, Relay Therapeutics, and Revolution Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $39.89 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Zymeworks’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.41 million and a GAAP net loss of $44.16 million. In comparison, last year the company earned a revenue of $27.11 million and had a GAAP net loss of $22.64 million

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).